|1.||Frei, Eva: 16 articles (09/2015 - 12/2005)|
|2.||Stiborová, Marie: 12 articles (01/2015 - 12/2005)|
|3.||Stiborova, Marie: 8 articles (09/2015 - 07/2006)|
|4.||Poljaková, Jitka: 8 articles (02/2012 - 12/2005)|
|5.||Kizek, Rene: 6 articles (09/2015 - 06/2010)|
|6.||Chen, P: 5 articles (08/2013 - 01/2008)|
|7.||Eckschlager, Tomas: 4 articles (09/2015 - 01/2011)|
|8.||Hrabeta, Jan: 4 articles (09/2015 - 07/2007)|
|9.||Eckschlager, Tomáš: 4 articles (02/2012 - 09/2008)|
|10.||Chen, Shih-Ping: 3 articles (11/2015 - 02/2009)|
01/01/2008 - "The viability results showed that the complexes with protonated ellipticine were effective in eradicating both cancer cells (viability <0.05), but their dilutions in water were not stable, leading to a fast decrease in their toxicity. "
01/15/2007 - "The study forms the basis to further predict the susceptibility of human cancers to ellipticine."
07/01/2006 - "The study forms the basis to further predict the susceptibility of human cancers to ellipticine."
11/01/2015 - "Erratum to: The collective nuclear migration of p53 and phosphorylated S473 of Akt during ellipticine-mediated apoptosis in human lung epithelial cancer cells."
09/01/2015 - "The collective nuclear migration of p53 and phosphorylated S473 of Akt during ellipticine-mediated apoptosis in human lung epithelial cancer cells."
07/18/2007 - "The results suggest the adduct formation as a new mode of antitumor action of ellipticine for leukemia."
07/01/1980 - "Formation of CHO cell colonies was inhibited by 50% following exposure to ellipticine for 2 hr at 6.0 microgram/ml or for 24 hr at 0.3 microgram/ml. Fifty % cell kill in asynchronously growing Friend leukemia and L1210 cells was obtained following exposure to ellipticine for 24 hr at 2.0 microgram/ml and 1.15 microgram/ml, respectively, whereas human peripheral blood lymphocytes required 66 hr exposure to 1.0 microgram/ml to kill 50% of the cells. "
08/13/1982 - "Ellipticine, a plant alkaloid effective against murine leukemias and solid tumors, is presently undergoing toxicological assessment prior to clinical trial. "
07/18/2007 - "DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells."
09/01/1976 - "The antitumor activity of a new derivative of ellipticine, 9-hydroxyellipticine (NSC 210717), was studied using L1210 mouse leukemia. "
|4.||Breast Neoplasms (Breast Cancer)
01/01/2014 - "Effects of ellipticine on ALDH1A1-expressing breast cancer stem cells--an in vitro and in silico study."
07/19/2002 - "VIP-ellipticine derivatives inhibit the growth of breast cancer cells."
06/18/2013 - "An assay with the telomerase repeat amplification protocol shows that ellipticine inhibits telomerase activity in MDAMB-231 breast cancer cell line extracts. "
12/01/2010 - "The alkyloid compound ellipticine derived from the berrywood tree is a topoisomerase II poison that is used in ovarian and breast cancer treatment. "
12/01/2005 - "Novel 1,3,9-triazacyclopenta[b]fluorene-4,10-diones and 1,3,9-triazacyclopenta[b]fluorene, analogue of ellipticine, were synthesised, and evaluated in vitro for their antiproliferative activity on various breast cancer cell lines."
02/01/2012 - "In previous studies, we found that ellipticine induces apoptosis in human neuroblastoma cells. "
09/01/2015 - "Exposure to the anticancer drug ellipticine inhibits efficiently growth of neuroblastoma cells and induces apoptosis in these cells. "
02/01/2012 - "On the basis of our results, it appears that ellipticine resistance in neuroblastoma is caused by a combination of overexpression of Bcl-2, efflux or degradation of the drug and downregulation of topoisomerases. "
02/01/2012 - "We also investigated whether ellipticine was able to induce resistance in the UKF-NB-4 neuroblastoma line and concluded that it may be possible after long-term treatment with increasing concentrations of ellipticine. "
02/01/2012 - "Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells."
|1.||elliptinium (elliptinium acetate)
|3.||DNA (Deoxyribonucleic Acid)
|4.||Type II DNA Topoisomerases (Topoisomerase II)
|7.||Cytochromes b5 (Cytochrome b5)
|8.||Cytochromes c (Cytochrome c)
|9.||Cytochrome P-450 CYP1A1 (CYP1A1)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)